Topics covered include: the global market in a historical context; and the outlook of "macro misery", having regard to unemployment, inflation, and the likelihood of recession and tighter monetary policy.
Copyright 2022 – Finance News Network
Source: Finance News Network
01 Mar 2021 - IVE Group Limited (ASX:IGL) Executive Chairman Geoff Selig talks about the company's strong 1H21 results on the back of a rebound in activity as the adverse impact of COVID disruptions diminishes.
Read More24 Jan 2024 - Investment expert Winston Sammut discusses recent M&A activity in the property sector, analyzing BWP Trust's bid for Newmarket and Aspen's offer for Eureka Holdings. Sammut shares insights on deal rationale, pricing concerns, and potential market implications.
Read More10 Mar 2025 - CEO Marc Voigt on Clinical Trials, Regulatory Milestones, and Market Growth
Read More01 Aug 2025 - AI platform revolutionising pharmaceutical quality control
Read More24 May 2021 - BluGlass Limited (ASX:BLG) Non-Executive Director Jean-Michel Pelaprat talks about joining BluGlass, his experience, and the future for BluGlass's gallium nitride technology.
Read More18 Sep 2023 - NOVONIX (ASX:NVX) achieved successful production with its Generation 3 Furnaces, meeting design goals for throughput, cost, and sustainability.
Read More01 Jul 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar discusses results from the company's study of its NYX-PCSK9i cholesterol-lowering compound.
Read More05 Nov 2024 - Paul Sanger interviews Anthony Noble, CEO of The Calmer Co (ASX:CCO), a leader in sustainable kava production. The Calmer Co aims to become the world's dominant kava company by promoting kava's calming and health benefits while improving the livelihoods of farmers in Fiji through fair pricing and a transparent supply chain.
Read More03 Jun 2020 - Cyclopharm (ASX:CYC) Managing Director and CEO James McBrayer provides an update on US FDA progress with Technegas, approval in Russia and potential use of Technegas in the diagnosis and management of COVID-19.
Read More29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
Read More
